MSA and COVID-19
Frederick, MD July 17, 2020 – MSA has decided to delay the full-time return to our Frederick offices indefinitely. Unfortunately,…
Mesa Science Associates and Bryn Pharma Publish Final of Three Pre-Clinical Studies of a New Approach to Treating Anaphylaxis
The third in a series of studies measured cerebrospinal fluid epinephrine pharmacokinetics, nasal mucosa effects, plasma epinephrine pharmacokinetics, and cardiovascular…
Dr. Kenneth Dretchen PhD has been appointed as a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Discovery Research Award Committee.
May 22, 2020 This committee review grant applications for Pre-doctoral, Post-doctoral and Research Starter Grants dealing with innovative approaches that…
Mesa Science Associates and Bryn Pharma Publish Second Pre-Clinical Study of a New Approach to Treating Anaphylaxis
The second in a series of three studies measured the pharmacokinetic and heart rate effects of intranasal epinephrine in dogs….
Mesa Science Associates and Bryn Pharma Publish Pre-Clinical Study of a New Approach to Treating Anaphylaxis
April 13, 2020 Mesa Science Associates Inc. (MSA) and Bryn Pharma LLC published the findings from the first of three…
MSA Team Works Toward Publications
March 16, 2020 MSA has submitted three manuscripts in high impact journals that report the results of pre-clinical experiments evaluating…
First of Three Patents Issued
February 17, 2020 Over the past two years, MSA has worked closely with Bryn Pharma to develop a new system…
On the Move
January 15, 2020 MSA recently made significant upgrades to our office space located within the Frederick Innovation Technology Center. Each…
Mesa Science Associates and Bryn Pharma Announce Initial Study of a New Approach to Treating Anaphylaxis
November 14, 2019 On November 10, 2019, Mr. Michael Mesa, President and CEO of Mesa Science Associates (MSA), announced the…
Bryn Pharma Research on Epinephrine Nasal Spray Presented at The American College of Allergy, Asthma and Immunology Annual Meeting
November 13, 2019 Preclinical Study of Intranasal Epinephrine Administration in Nasal Congestion Model Demonstrated Faster Absorption of Epinephrine in Canines…
MSA News
Nov
10,
2022
MesaGreen Pharmaceutical Company Files an Investigational New Animal Drug Application
FREDERICK, MD. Nov. 10, 2022—MesaGreen Pharmaceutical Company announced today that the company has filed an Investigational New Animal Drug (INAD)…
Jul
18,
2022
Mesa Science Associates Receives Grant to Begin Study of a Treatment for Marfan Syndrome
Mesa Science Associates Inc. (MSA) received a Phase I Small Business Innovative Research Grant (SBIR) from the National Institutes of…
Jan
14,
2022
NIH SBIR Grant application 1/5/2022
Mesa Science Associates has applied for an NIH Small Business Innovative Research (SBIR) Grant from the National Institutes of Health…
